James Richard Porter Sells 17,890 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 17,890 shares of Nuvalent stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $97.32, for a total transaction of $1,741,054.80. Following the transaction, the chief executive officer directly owned 288,172 shares of the company’s stock, valued at $28,044,899.04. This represents a 5.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

James Richard Porter also recently made the following trade(s):

• On Tuesday, January 6th, James Richard Porter sold 9,543 shares of Nuvalent stock. The stock was sold at an average price of $97.16, for a total transaction of $927,197.88.
• On Thursday, October 16th, James Richard Porter sold 27,000 shares of Nuvalent stock. The stock was sold at an average price of $90.63, for a total transaction of $2,447,010.00.

Nuvalent Trading Down 3.9%

NASDAQ:NUVL opened at $102.67 on Friday. The stock has a market capitalization of $7.47 billion, a P/E ratio of -19.30 and a beta of 1.32. Nuvalent, Inc. has a 1 year low of $55.53 and a 1 year high of $112.88. The firm has a 50 day moving average of $102.73 and a 200-day moving average of $89.01.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings results on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same period last year, the company posted ($1.28) earnings per share. As a group, analysts forecast that Nuvalent, Inc. will post -3.86 EPS for the current fiscal year.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: Analysts remain constructive — several firms have recently initiated/raised coverage and price targets (Cantor Fitzgerald, Leerink, Baird, Goldman Sachs, Truist among others), leaving a consensus target near $138 that supports longer-term upside. MarketBeat Nuvalent Coverage
• Neutral Sentiment: Company fundamentals reminder — Nuvalent is clinical-stage (lead assets NVL‑520, NVL‑655) and reported an EPS miss on Oct. 30 (($1.70) vs. ($1.39) expected); pipeline readouts and clinical data remain the key medium-term catalysts/risks. Earnings / Profile
• Neutral Sentiment: Institutional ownership is very high (~97%), and some small funds added modest positions recently — this reduces free-float liquidity but can amplify moves when insiders trade. Institutional Activity
• Negative Sentiment: Concentrated insider selling: CEO James R. Porter sold large blocks (17,890 shares on Jan. 5 and 9,543 shares on Jan. 6 at ~ $97 / share), a material reduction in his position that likely weighs on sentiment. SEC Filing – CEO Sales
• Negative Sentiment: CFO Alexandra Balcom and other insiders (director Christopher D. Turner, Deborah A. Miller, Henry E. Pelish) also sold multiple tranches on Jan. 5–6 (several thousand shares each), collectively trimming insider stakes and adding selling pressure. SEC Filing – CFO Sales SEC Filing – Turner SEC Filing – Miller SEC Filing – Pelish

Analyst Upgrades and Downgrades

NUVL has been the topic of several research reports. Barclays set a $152.00 price target on shares of Nuvalent in a research report on Monday, November 17th. Robert W. Baird boosted their target price on shares of Nuvalent from $112.00 to $158.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research note on Wednesday, October 8th. Piper Sandler boosted their price objective on shares of Nuvalent from $112.00 to $128.00 and gave the stock an “overweight” rating in a research report on Monday, October 27th. Finally, Wedbush reaffirmed an “outperform” rating and set a $125.00 price objective (up previously from $120.00) on shares of Nuvalent in a report on Monday, November 17th. Fifteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nuvalent presently has an average rating of “Moderate Buy” and a consensus target price of $138.33.

Hedge Funds Weigh In On Nuvalent

Several hedge funds have recently added to or reduced their stakes in NUVL. GAMMA Investing LLC boosted its holdings in Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Nuvalent in the 3rd quarter valued at approximately $38,000. Eastern Bank bought a new position in Nuvalent during the 3rd quarter worth approximately $52,000. Persistent Asset Partners Ltd acquired a new position in Nuvalent during the second quarter valued at approximately $88,000. Finally, Farther Finance Advisors LLC increased its stake in Nuvalent by 9,230.8% in the second quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after purchasing an additional 1,200 shares in the last quarter. Institutional investors and hedge funds own 97.26% of the company’s stock.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.